European Medicines Agency validates application for CAR-T cell therapy Breyanzi, for relapsed or refractory follicular lymphoma – BMS
Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application to expand the indication for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed… read more.
